Follicular lymphoma medical therapy: Difference between revisions
No edit summary |
|||
Line 12: | Line 12: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hematology]] | |||
[[Category:Types of cancer]] | |||
[[Category:Oncology]] |
Revision as of 16:39, 21 September 2012
Follicular lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Follicular lymphoma medical therapy On the Web |
American Roentgen Ray Society Images of Follicular lymphoma medical therapy |
Risk calculators and risk factors for Follicular lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
There is no consensus regarding the best treatment algorithm, but watch-and-wait policies, alkylators, anthracycline-containing regimens (eg. CHOP), rituximab, autologous and allogenic hematopoietic stem cell transplantation have all been applied. The exception is localized disease, which can be cured by local irradiation. The typical pattern is one of good responses from treatment, followed by relapses some years later. Some patients may never need treatment.